Pfizer Unveils Oncology Business Unit, Gives Failed Compounds Another Try
This article was originally published in The Pink Sheet Daily
Executive Summary
CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.
You may also be interested in...
Echoing Pfizer, OSI To Put IGF-1R Candidate In Phase III
Company plans to piggyback the potential lung-cancer drug – combined with Tarceva – on current Phase I study, as investors await SATURN and ATLAS details at ASCO.
Echoing Pfizer, OSI To Put IGF-1R Candidate In Phase III
Company plans to piggyback the potential lung-cancer drug – combined with Tarceva – on current Phase I study, as investors await SATURN and ATLAS details at ASCO.
As Pfizer Faces Brand Drug Challenges, Management Pushes Cost Cuts
Executives head off questions about dramatic transformational changes during third quarter earnings call; Fablyn is delayed three months by FDA.